Matthieu Roulleaux Dugage

Medical oncologist |
Immuno-oncology - Drug Development Department |
Gustave Roussy

[TOP 14 Rugby @top14rugby]

2 ans de rugby. Une passion révélée 🏉

Thierry Dusautoir est allé à la rencontre de Frémy, jeune talent du @RCPXV, pour échanger autour de son histoire, de sa passion et de ce que le rugby lui a apporté.

Avec @Paramourdurugby, les talents se révèlent.

#TOP14 | #RencontresTerrainFavorable

[Jean-Noël Barrot @jnbarrot]

@LAGovJeffLandry @realDonaldTrump Greenland belong to greelanders. Greenland is european territory.

[Matthieu Roulleaux Dugage @Matthieurd]

Un grand merci à l’@IFCTlung et son conseil scientifique pour ce prix et leur soutien à notre projet.

AUREMESO permettra, je l’espère, l’identification de nouvelles cibles et de nouveaux biomarqueurs pour les patients traités pour un mésothéliome !

@GustaveRoussy

[Cancer Core Europe (CCE) @CancerCoreEU]

🚀 Kicking off the 2nd #CCETRYTRAC face-to-face meeting — this time at @NCT_HD, Germany!

💡 Excited for three days of learning, exchange, and networking.

@VHIO @DKFZ @IstTumori @karolinskainst @NKI_nl @GustaveRoussy @CRUKCamCentre

[Benjamin Besse @BenjaminBesseMD]

Up to 50% of patients with metastatic cancer develop lung metastases, linked to poor prognosis and impaired quality of life.
Our Nature Reviews Disease Primers article unpacks biology, diagnosis & treatment strategies. @LodovicaZullo @GustaveRoussy https://t.co/i4CSso8aY4

[Stephen V Liu, MD @StephenVLiu]

Comparison of EGFR NSCLC transformed to #SCLC vs de novo SCLC @LungCaJournal. OS shorter with transformed SCLC esp with high neuroendocrine marker expression. In transformed SCLC, OS with chemo-immunotherapy superior to chemo +/- TKI (15.4m vs 8.5m).

https://t.co/0QqZ3JWXn4

[Christophe Massard @drcmassard]

New drugs @ASCO2025 @GustaveRoussy

[Harvard University @Harvard]

Without its international students, Harvard is not Harvard. https://t.co/V8uvTNaL64

[Matthieu Roulleaux Dugage @Matthieurd]

@GerardAraud Indépendamment de l’épineuse question du salaire de ces chercheurs, il faut surtout financer leurs projets, et avoir les infrastructures pour les accueillir. Il faudrait un investissement massif, probablement non réaliste.

[Matthieu Roulleaux Dugage @Matthieurd]

IL-6R blockade to uncouple toxicité ans efficace in ICB-treated patients ?

Our editorial @Annals_Oncology 👇

Thank you to coauthors !!

[Annals of Oncology @Annals_Oncology]

📢New editorial in press: Breaking the link: IL-6 targeting to uncouple toxicity and efficacy in patients treated with immune checkpoint blockade @Matthieurd
https://t.co/IBltAOTlYP

[Annals of Oncology @Annals_Oncology]

New article in press: Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study. @peters_solange
https://t.co/DBXMYDHd62

[Christophe Massard @drcmassard]

New drugs ESMO2024

[Jean-Yves Blay @jeanyvesblay]

First Cellular Therapy approved for a solid tumor! In synovial sarcoma an orphan tumor!

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

[Eric Vivier @EricVivier1]

Thrilled to announce the publication of our latest research in Nature Immunology. Joining forces with 20 laboratories in Europe and USA, we identified the three prominent NK cell subsets in human: NK1, NK2, and NK3: https://t.co/VMPTPpiLOV

[Matthieu Roulleaux Dugage @Matthieurd]

Wonderful results, once again highlighting the immunosuppressive effects of liver metastases in patients treated with immunotherapy (impressive waterfall plot)

[Anthony El-Khoueiry @DrElkhoueiry]

Honored to have served as lead investigator on phase I study of botensilimab with expansion in MSS CRC; activity across cold tumors! Thank you to all co-authors and Agenus for the great collaboration. Gratitude to our amazing phase I team at USC Norris!
https://t.co/FOf9dwEqPh

[Patrick Forde @FordePatrick]

Anyone still think we should not be using immune checkpoint inhibitors before surgery? Or that use of adjuvant ICI only is as good as neoadjuvant ICI?
Phase 3 trial in resectable melanoma now in @NEJM concurrent with plenary by @ProfCUBlankNKI #ASCO24
https://t.co/xbB8eYHr0d

[Eric Topol @EricTopol]

It had me at "the normal intact adult pancreas harbours hundreds of pancreatic intraepithelial neoplasias (PanINs), almost all with oncogenic KRAS hotspot mutations"
Spatial omics of pancreatic cancer
https://t.co/mx8HlxUith
@Nature @lauradelongwood @deniswirtz @AshleyKiemen

[Matthieu Roulleaux Dugage @Matthieurd]

@RobertoFerrara_ @AIRC_it @MyUniSR Wonderful design 👏
Great to see resistance biomarkers prospectively investigated & LIPI included as a stratification factor.

[Eric Topol @EricTopol]

Our most complex biologic system—immunity—is reviewed in 3 new @CellCellPress papers, open-access
Adaptive
https://t.co/rJRBnV7u8I
Innate
https://t.co/PMKA6KgL7R
New insights
https://t.co/rJRBnV7u8I @RMedzhitov

[JAMA Oncology @JAMAOnc]

ICI-chemotherapy did not improve survival compared with ICI alone in older adults with previously untreated advanced NSCLC, but increased the incidence of grade 3 and higher immune-related adverse events. https://t.co/KD2EnxmUfo